ASPIRA PATHLAB & DIAGNOSTICS | KAYA | ASPIRA PATHLAB & DIAGNOSTICS / KAYA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -12.7 | -5.3 | - | View Chart |
P/BV | x | 2.4 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS KAYA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
KAYA Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / KAYA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 424 | 17.7% | |
Low | Rs | 26 | 241 | 10.6% | |
Sales per share (Unadj.) | Rs | 14.0 | 288.5 | 4.9% | |
Earnings per share (Unadj.) | Rs | -0.1 | -89.0 | 0.1% | |
Cash flow per share (Unadj.) | Rs | 1.5 | -17.6 | -8.3% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | -81.6 | -15.2% | |
Shares outstanding (eoy) | m | 10.29 | 13.06 | 78.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 1.2 | 310.7% | |
Avg P/E ratio | x | -583.7 | -3.7 | 15,617.1% | |
P/CF ratio (eoy) | x | 34.6 | -18.9 | -182.9% | |
Price / Book Value ratio | x | 4.1 | -4.1 | -99.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 4,345 | 11.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 1,735 | 3.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 3,767 | 3.8% | |
Other income | Rs m | 3 | 45 | 7.1% | |
Total revenues | Rs m | 148 | 3,812 | 3.9% | |
Gross profit | Rs m | 16 | 140 | 11.3% | |
Depreciation | Rs m | 16 | 933 | 1.7% | |
Interest | Rs m | 4 | 415 | 1.0% | |
Profit before tax | Rs m | -1 | -1,163 | 0.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 0 | - | |
Profit after tax | Rs m | -1 | -1,163 | 0.1% | |
Gross profit margin | % | 11.0 | 3.7 | 295.7% | |
Effective tax rate | % | 0 | 0 | - | |
Net profit margin | % | -0.6 | -30.9 | 2.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 1,426 | 4.1% | |
Current liabilities | Rs m | 16 | 2,486 | 0.6% | |
Net working cap to sales | % | 29.5 | -28.2 | -104.9% | |
Current ratio | x | 3.7 | 0.6 | 644.3% | |
Inventory Days | Days | 88 | 28 | 309.1% | |
Debtors Days | Days | 590 | 34 | 1,721.6% | |
Net fixed assets | Rs m | 115 | 2,274 | 5.0% | |
Share capital | Rs m | 103 | 131 | 78.8% | |
"Free" reserves | Rs m | 25 | -1,196 | -2.1% | |
Net worth | Rs m | 128 | -1,066 | -12.0% | |
Long term debt | Rs m | 10 | 1,421 | 0.7% | |
Total assets | Rs m | 173 | 3,700 | 4.7% | |
Interest coverage | x | 0.8 | -1.8 | -43.8% | |
Debt to equity ratio | x | 0.1 | -1.3 | -5.7% | |
Sales to assets ratio | x | 0.8 | 1.0 | 81.9% | |
Return on assets | % | 1.9 | -20.2 | -9.4% | |
Return on equity | % | -0.7 | 109.1 | -0.6% | |
Return on capital | % | 2.4 | -210.5 | -1.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0.9 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 36 | 0.0% | |
Fx inflow | Rs m | 0 | 124 | 0.0% | |
Fx outflow | Rs m | 0 | 36 | 0.0% | |
Net fx | Rs m | 0 | 89 | 0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 628 | -0.0% | |
From Investments | Rs m | 2 | -398 | -0.4% | |
From Financial Activity | Rs m | -9 | -183 | 5.1% | |
Net Cashflow | Rs m | -8 | 53 | -14.8% |
Indian Promoters | % | 18.9 | 59.8 | 31.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 2.7 | - | |
FIIs | % | 0.0 | 0.7 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.1 | 40.2 | 201.7% | |
Shareholders | 1,351 | 20,890 | 6.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | KAYA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -3.03% | 7.26% | -1.23% |
1-Month | -6.70% | 10.86% | 1.07% |
1-Year | -6.06% | 14.28% | 50.86% |
3-Year CAGR | 0.18% | 13.81% | 14.38% |
5-Year CAGR | -1.94% | -12.38% | 19.01% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the KAYA share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.9% stake in the company. In case of KAYA the stake stands at 59.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of KAYA.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
KAYA paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of KAYA.
For a sector overview, read our pharmaceuticals sector report.
It was indeed a volatile trading session for Indian share markets today. Benchmark indices swung between gains and losses throughout the day.